MYCOPLASMA INFECTION: CLINICAL TYPES, VARIATIONS OF CLINICAL COURSE AND DIAGNOSTIC MISTAKES
https://doi.org/10.15690/vsp.v12i6.884
Abstract
Aim: to assess clinical course of various types of mycoplasma infection during the last epidemic (September 2012 – February 2013) according to the positive results of serological analyses. Patients and methods: 3553 laboratory tests were performed, 177 (20%) positive results of mycoplasma were detected. During the study clinical types, gender and age of patients were analyzed; special characteristics of clinical course of mycoplasma pneumonia were identified. Results: among 78 patients with pneumonia severe form was detected only in one. Twenty five percent of patients had ENT-diseases. The authors performed comparative analysis of antibacterial treatment (first-line and macrolides). The duration of X-ray changes depended on treatment scheme; the best results were achieved in children who were administered combined treatment with first-line (cephalosporin) and macrolide in suspension. Conclusions: during the period of 2012–2013 yy pneumonia has had a moderate clinical course, rarely — with complications. In 25% of children diseases of ENT organs were diagnosed. Mycoplasma was most often associated with chlamydia and types 1 and 2 of herpes simplex viruses, which is necessary to be considered in determination of therapy regimen. In treatment it is preferably to use combination of cephalosporin and macrolide in suspension.
About the Authors
M.S. Savenkova
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Savenkova Marina Sergeevna, Doctor of Medical Science, Professor of the Department of Clinical functional diagnosis
Russian Federation
Savenkova Marina Sergeevna, Doctor of Medical Science, Professor of the Department of Clinical functional diagnosis
M. P. Savenkov
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
E. R. Samitova
V.E. Morozov Pediatric Clinical Hospital, Moscow,
Russian Federation
Russian Federation
A. V. Bullikh
V.E. Morozov Pediatric Clinical Hospital, Moscow
Russian Federation
Russian Federation
I. A. Zhuravleva
V.E. Morozov Pediatric Clinical Hospital, Moscow
Russian Federation
Russian Federation
D. V. Yakubov
N.I. Pirogov Russian National Research Medical University, Moscow;
V.E. Morozov Pediatric Clinical Hospital, Moscow
Russian Federation
Russian Federation
E. S. Kuznetsova
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
CONFLICT OF INTEREST
The study was supported by Teva, LLC.
References
1. Khadisova M. K., Feklisova L. V., Rusanova E. V., Kudryavtseva E. N., Tselipanova E. E. Kataralniy respiratorniy sindrom u detey s mikoplazmozom [Catarrhal respiratory syndrome in children with mycoplasmosis]. Infektsionniy bolnoy — Infectious patient. 2012; 10 (4): 85–86.
2. Popova O. P., Petrova M. S., Fyodorova I. M., Koteleva S. I., Abramova E. N. Kliniko-immunologicheskiye osobennosti sochetannogo techeniya koklyusha i respiratornogo mikoplazmoza u detey [Clinical and immunological features of the combined flow of pertussis and respiratory mycoplasmosis in children]. Infektsionniy bolnoy — Infectious patient. 2012; 10 (2): 43–48.
3. Ovsyannikova E. M., Korovina N. A. Analiz klinicheskogo sluchaya ostrogo virusno-bakterialno-mikoplazmennogo respiratornogo zabolevaniya: etiopatogeneticheskiye osobennosti i taktika lecheniya [Analysis of the clinical case of acute viral, bacterial and mycoplasma respiratory disease: Etiopathogenic characteristics and treatment strategy]. Consilium medicum (Pediatriya) [Consilium medicum (Pediatrics)]. 2011; 2: 24–27.
4. Arleevskiy I. P., Ganeeva L. A., Safin I. N., Chernova O. A., Chernov V. M. Persistiruyushchaya mikoplazmennaya infektsiya kak faktor riska razvitiya ostrogo infarkta miokarda [Persistent mycoplasma infection as a risk factor for acute myocardial infarction development]. Kardiologiya — Cardiology. 2001; 3: 45–46.
5. Waites K. B., Katz B., Shelonka R. L. Mycoplasmas and ureaplasmas as neonatal pathogens. Сlin. Microbiol. Rev. 2005; 18 (4): 757–789.
6. Blasi F. Atypical pathogens and respiratory tract infections. Eur. Respir. J. 2004; 24 (1): 171–181.
7. Global Atlas of Asthma. EAACI. C. A. Akdis, I. Agache (eds.). 2013. 179 p.
8. Savenkova M., Savenkov M. Khlamidiyno-mikoplazmennye infektsii u detey [Chlamydia and mycoplasma infection in children]. Moscow, Miklosh Publ., 2012. 291 p.
9. Strachunskiy L. S., Kozlov S. N. Makrolidy v sovremennoy klinicheskoy praktike [Macrolides in modern clinical practice]. Smolensk, Rusich Publ., 1998. 303 p.
10. Antibakterialnaya terapiya. Prakticheskoye rukovodstvo [Antibiotic therapy. Practical guide]. Edited by L. S. Strachunskiy, Yu. B. Belousov, S. N. Kozlov. Moscow, Borges Publ., 2000. P. 42–47, 125–126.
11. Odenholt-Tornqvist I., Lowdin E., Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob. Agents Chemother. 1995; 39: 221–226.
12. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004; 125: 41–51. 13. Antibiotics and the Lung. In: European Respiratory Monograph. M. Cazzola, F. Blasi, S. Ewig (eds.). 2004; 9: 28 p.
13. Labro M. T. Antibiotics as anti-inflammatory drugs. Curr. Opin. Investig. Drugs. 2002; 3: 61–68.
14. Veselov A. V., Kozlov R. S. Azitromitsin: sovremennye aspekty klinicheskogo primeneniya [Azithromycin: Modern aspects of clinical application]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya — Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8 (1): 18–32.
15. Stetsyuk O. U., Andreeva I. V., Kolosov A. V., Kozlov R. S. Bezo pasnost i perenosimost antibiotikov v ambulatornoy praktike [Safety and tolerability of antibiotics in ambulatory practice]. KMAKh [CMAC]. 2011; 13 (1): 67–84.
16. Kozlov R. S., Veselov A. V. Makrolidy i ketolidy [Macrolides and ketolides]. In the book: Vnebolnichnye infektsii dykhatelnykh putey: diagnostika i lecheniye [Community-acquired respiratory tract infections: diagnosis and treatment]. Moscow, 2008. P. 49–65.
17. Schito G., Debbia E., Marchese A. The evolving of antibiotic resistance in Europe: new data from the Alexander project. J. Antimicrob. Chemother. 2000; 46 (Suppl. 3): 3–9.
18. Kozlov R. S., Sivaya O. V., Krechikova O. I., Ivanchik N. V. Dina mika rezistentnosti S. pneumoniae k antibiotikam v Rossii za period 1999–2009 gg.: rezultaty mnogotsentrovogo prospektivnogo issledovaniya PeGAS [Dynamics of S. pneumoniae resistance to antibiotics in Russia for the period of 1999–2009: Results of a multicenter prospective study PeGAS]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya — Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12 (4): 329–341.
19. Harris J. A., Kolokathis A., Campbell M., Cassell G. H., Hammerschlag M. R. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. 1998; 10: 865–871.
20. Yong-Dong Y. Changes of immune function in children with refractory Mycoplasma pneumonia and effects of pidotimod. Clin. Pediatr. 2008; 26 (7): 570–572.
21. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumonia infection with special reference to pneumonia. J. Infect. Chemother. 2010; 16: 162–169.
Review
For citations:
Savenkova M., Savenkov M.P., Samitova E.R., Bullikh A.V., Zhuravleva I.A., Yakubov D.V., Kuznetsova E.S. MYCOPLASMA INFECTION: CLINICAL TYPES, VARIATIONS OF CLINICAL COURSE AND DIAGNOSTIC MISTAKES. Current Pediatrics. 2013;12(6):108-114. (In Russ.) https://doi.org/10.15690/vsp.v12i6.884
Views:
1454
Email this article 
